| Title |
Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
|
|---|---|
| Published in |
European Journal of Clinical Microbiology & Infectious Diseases, February 2014
|
| DOI | 10.1007/s10096-014-2070-6 |
| Pubmed ID | |
| Authors |
A. Batirel, I. I. Balkan, O. Karabay, C. Agalar, S. Akalin, O. Alici, E. Alp, F. A. Altay, N. Altin, F. Arslan, T. Aslan, N. Bekiroglu, S. Cesur, A. D. Celik, M. Dogan, B. Durdu, F. Duygu, A. Engin, D. O. Engin, I. Gonen, E. Guclu, T. Guven, C. A. Hatipoglu, S. Hosoglu, M. K. Karahocagil, A. U. Kilic, B. Ormen, D. Ozdemir, S. Ozer, N. Oztoprak, N. Sezak, V. Turhan, N. Turker, H. Yilmaz |
| Abstract |
The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 130 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 130 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 13% |
| Researcher | 16 | 12% |
| Student > Master | 16 | 12% |
| Student > Bachelor | 13 | 10% |
| Professor | 10 | 8% |
| Other | 31 | 24% |
| Unknown | 27 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 8% |
| Immunology and Microbiology | 9 | 7% |
| Agricultural and Biological Sciences | 6 | 5% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Other | 16 | 12% |
| Unknown | 39 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2015.
All research outputs
#13,406,705
of 22,751,628 outputs
Outputs from European Journal of Clinical Microbiology & Infectious Diseases
#1,599
of 2,769 outputs
Outputs of similar age
#176,880
of 336,464 outputs
Outputs of similar age from European Journal of Clinical Microbiology & Infectious Diseases
#28
of 41 outputs
Altmetric has tracked 22,751,628 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,769 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,464 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.